Results 81 to 90 of about 218,137 (296)

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Regulation of Neuroinflammation through Programmed Death-1/Programmed Death Ligand Signaling in Neurological Disorders

Frontiers in Cellular Neuroscience, 2014
Immune responses in the central nervous system (CNS), which involve both resident glial cells and infiltrating peripheral immune cells, play critical roles in the progress of brain injuries and neurodegeneration.
Shangfeng eZhao, Shangfeng eZhao, fengwu eli, Rehana K Leak, Jun eChen, Xiaoming eHu, Xiaoming eHu   +6 more
doaj   +1 more source

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]

, 2019
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core   +1 more source

Effect of Insulin-Like Growth Factor-1 (IGF-1) on the expression of NFκB and cFLIP in Bovine Granulosa Cells [PDF]

, 2014
Infertility, often attributed to follicular atresia, is a growing problem in the agricultural industry. Programmed cell death, also known as apoptosis, is a contributing factor of follicular atresia.
Docos, Samantha Kathleen
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Bcl-2 protein family: Implications in vascular apoptosis and atherosclerosis [PDF]

, 2006
Apoptosis has been recognized as a central component in the pathogenesis of atherosclerosis, in addition to the other human pathologies such as cancer and diabetes.
A Ashkenazi, A Bakhshi, A Basu, A Gross, A Letai, A Mandic, A Nechushtan, A Nechushtan, A Ruiz-Vela, A Saxena, A Schinzel, A Strasser, AE Rusinol, AJ Bruce-Keller, AP Gilmore, AS Belzacq, AZ Badrichani, B Antonsson, B Fadeel, B Hufnagel, C Adrain, C Borner, C Napoli, C Scaffidi, C Soldani, D de Moissac, D Decaudin, D Heiser, DE Wood, DG Kirsch, DJ Veis, DM Finucane, DW Dickson, E Oda, EA Slee, EH Cheng, EJ Ackermann, FA Sinicrope, G Basanez, G Molostvov, G van Loo, G van Loo, GD Norata, GJ Griffiths, GV Putcha, H He, H Kataoka, H Li, HH Kim, HS Lee, Huveyda Basaga, I Marzo, I Marzo, J Chen, J Han, J Liu, J Masuda, J Yang, J Yu, J Yu, J Zha, JC Reed, JL Bodmer, K Nakano, K Ochs, K Sakurai, K Wang, K Yamamoto, KM Hajra, KM Murphy, L He, M Aritomi, M del Mar Martinez-Senac, M Narita, M Nguyen, M Sata, M Sata, M Sattler, MB Bogdanov, MC Wei, MJ Pollman, MM Kockx, MR Bennett, MR Morissette, MR Sprick, MY Donath, N Donovan, N Mirkovic, N Motoyama, O Kutuk, O Meilhac, OW Rokhlin, Ozgur Kutuk, P Pauletto, PM Yao, Q Huang, R Rashmi, R Ross, R Ross, RA Gottlieb, RJ Alvarez, RM Kluck, S Conus, S Desagher, S Dramsi, S Grethe, S Krajewski, S Nouraini, S Ottilie, S Shimizu, S Takarada, S Vicca, S Vicca, SA Keogh, SA Memon, SC Ruffolo, SJ Korsmeyer, SJ Korsmeyer, SJ Neame, SL Schendel, SN Willis, SR Datta, SR Datta, SW Muchmore, SY Hsu, T Ito, T Lee, T Shibue, TD Littlewood, TS Soderstrom, UK Messmer, V Mikhailov, V Mikhailov, V Petronilli, V Petronilli, W Zhang, X Cao, XM Sun, Y Deng, Y Gazitt, Y Konishi, Y Liang, Y Michowitz   +142 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. [PDF]

, 2019
BACKGROUND:Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is ...
Baste, Neus, Clayburgh, Daniel, Cohen, Ezra EW, Fountzilas, George, Fujii, Takashi, Khaliq, Asud, Kim, Edward S, Lin, Derrick, Lipworth, Loren, Mehlhorn, Holger, Melillo, Giovanni, Pai, Sara I, Resteghini, Carlo, Shara, Nawar, Shire, Norah, Stokes, Michael, Twumasi-Ankrah, Philip, Wang, Huifen, Wildsmith, Sophie, Zhang, Jun   +19 more
core   +1 more source

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. [PDF]

, 2020
BACKGROUND/AIM:mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Increasing evidence suggests treatment outcome depending on tumor cell PD-L1 expression.
Belka, Claus, Eze, Chukwuka, Gennen, Kathrin, Karin, Monika, Käsmann, Lukas, Manapov, Farkhad, Neumann, Jens, Orth, Michael, Reu, Simone, Roengvoraphoj, Olarn, Taugner, Julian, Tufman, Amanda   +11 more
core   +1 more source